NovoCure Limited
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-61.7M | $-131.8M | $-111.6M | $-80.7M | $-77.4M |
| Depreciation & Amortization | $7.7M | $5.7M | $3.2M | $2.0M | $1.2M |
| Depreciation | $2.0M | $1.7M | $1.3M | $886.0K | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $27.1M | $22.1M | $11.9M | $4.6M | $5.1M |
| Net Cash from Operating Activities | $-33.1M | $-107.6M | $-99.9M | $-74.2M | $-52.7M |
| Investing Activities | |||||
| Capital Expenditures | $7.4M | $5.7M | $4.7M | $849.0K | $2.2M |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $8.6M | $13.0M | — | — | — |
| Financing Activities | |||||
| Dividends Paid | $0 | $0 | $0 | — | — |
| Stock Repurchases | — | — | $5.0K | — | — |
| Net Cash from Financing Activities | $5.2M | $75.1M | — | — | — |
| Net Change in Cash | $-21.2M | $-19.6M | $61.8M | $-118.3M | $141.0M |
| Free Cash Flow | $-40.5M | $-113.3M | $-104.6M | $-75.1M | $-54.9M |